TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24617818

Group type: EXPERIMENTAL
Intervention: Carprofen (NSAID)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 22104040

Group type: EXPERIMENTAL
Intervention: Stimulation at 15 Hz above cramp threshold frequency (TF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stimulation at 20 Hz above cramp threshold frequency (TF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cramp threshold frequency (TF)
Number of subjects: 20
Study: 19932946

Group type: EXPERIMENTAL
Intervention: Adjuvant chest wall radiotherapy (PMRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 0
Study: 18236178

Group type: EXPERIMENTAL
Intervention: Partial weight bearing (P)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Full weight bearing (F)
Number of subjects: 43
Study: 15791442

Group type: EXPERIMENTAL
Intervention: Nicorandil (group A, n=25)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (group B, n=25)
Number of subjects: 58
Study: 12472909

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg day-1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9862577

Group type: EXPERIMENTAL
Intervention: Expression of truncated hHb1 hair keratin in breast carcinomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro study of hHb1 expression
Number of subjects: 0
Study: 7897047

Group type: EXPERIMENTAL
Intervention: Reward and response costs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Response costs only
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reward only
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 1699985

Group type: EXPERIMENTAL
Intervention: Pharmalgen
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Allpyral
Number of subjects: 80

Group type: COMPARATOR
Intervention: Histamine chloride (placebo)
Number of subjects: 80
Study: 580285

Group type: EXPERIMENTAL
Intervention: Penfluridol, administered orally, once weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 0
Study: 31586203

Group type: EXPERIMENTAL
Intervention: Increased miR-203 levels in ovarian cancer patients
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: miR-203 expression
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Integration of miR-203 levels with established disease prognostic markers
Number of subjects: 225
Study: 30196481

Group type: EXPERIMENTAL
Intervention: Dual focus (DF) MiSight® contact lenses (CLs)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Single-vision (SV) spectacles
Number of subjects: 74
Study: 28401849

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Enhanced community standard control group
Number of subjects: 125
Study: 26115467

Group type: EXPERIMENTAL
Intervention: Surgical clipping
Number of subjects: 408

Group type: COMPARATOR
Intervention: Endovascular coiling
Number of subjects: 408
Study: 23748114

Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg every 4 weeks (Q4wk)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Fulranumab 6 mg every 8 weeks (Q8wk)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Fulranumab 10 mg every 8 weeks (Q8wk)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Fulranumab (various doses)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 21199488

Group type: EXPERIMENTAL
Intervention: Learn to think (LTT) curriculum, one activity every 2 weeks for 4 school years
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 166
Study: 19478622

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg body weight of gadobenate dimeglumine (Gd‐BOPTA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.2 mmol/kg body weight of gadopentetate dimeglumine (Gd‐DTPA)
Number of subjects: 20
Study: 17227809

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone (DG)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vaginal micronized progesterone
Number of subjects: 6
Study: 15287372

Group type: EXPERIMENTAL
Intervention: Dynamic exercise during euglycemic insulin clamp
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dynamic exercise during hyperglycemic insulin clamp
Number of subjects: 12
Study: 11706668

Group type: EXPERIMENTAL
Intervention: DEC 300 mg per day for 12 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: DEC
Number of subjects: 98
Study: 9152515

Group type: EXPERIMENTAL
Intervention: Selenized yeast tablet (200 micrograms daily for 4 years)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo yeast tablet (identical to Se tablet)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Selenized table salt (supplemented)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Withdrawal of Se treatment
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cessation of Se treatment
Number of subjects: 226
Study: 8265093

Group type: EXPERIMENTAL
Intervention: EAP-1 (doxorubicin 20 mg/m2 on days 1 and 7, cisplatin 40 mg/m2 on days 2 and 8, etoposide 120 mg/m2 on days 4-6)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: EAP-2 (doxorubicin 40 mg/m2 on day 1, cisplatin 80 mg/m2 in 3 divided doses on days 1-3, etoposide 100 mg/m2 on days 1-3)
Number of subjects: 63
Study: 3312216

Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 21

Group type: COMPARATOR
Intervention: Scarlet red
Number of subjects: 21
Study: 31385178

Group type: EXPERIMENTAL
Intervention: Double-dose nicorandil (30 mg/day)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Usual-dose nicorandil (15 mg/day)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (hydration only)
Number of subjects: 330
Study: 27911566

Group type: EXPERIMENTAL
Intervention: Pedometer-directed step targets during pulmonary rehabilitation (PR) for 8 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control intervention (PR comprising 8 weeks, two supervised sessions per week)
Number of subjects: 152
Study: 25875256

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily for 12 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 111
Study: 23573993

Group type: EXPERIMENTAL
Intervention: Transparent cap‐assisted esophagogastroduodenoscopy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional esophagogastroduodenoscopy
Number of subjects: 70
Study: 21246232

Group type: EXPERIMENTAL
Intervention: AV/pN-gapA (GAPDH-display strain)
Number of subjects: 0
Study: 19947068

Group type: COMPARATOR
Intervention: Tramadol alone
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Tramadol plus remifentanil
Number of subjects: 133

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Morphine plus remifentanil
Number of subjects: 133
Study: 16107490

Group type: EXPERIMENTAL
Intervention: Recurrent acute otitis media
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Persistent middle ear effusion
Number of subjects: 210
Study: 15335150

Group type: EXPERIMENTAL
Intervention: Self-locating catheter
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Classic Tenckhoff catheter
Number of subjects: 1000
Study: 11496616

Group type: EXPERIMENTAL
Intervention: (S)-ketamine/propofol (0.33-1.0 mg/kg BW/h (S)-ketamine + 1-3 mg/kg BW/h propofol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: (S)-ketamine/midazolam (0.33-1.0 mg/kg BW/h (S)-ketamine + 0.033-0.1 mg/kg BW/h midazolam)
Number of subjects: 30

Group type: COMPARATOR
Intervention: (S)-ketamine/midazolam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: (S)-ketamine/propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 30
Study: 9930476

Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 32

Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (Centrifugal and Roller pumps)
Number of subjects: 32
Study: 8061102

Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus cytarabine (MTT+Ara‐C)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Daunomycin plus cytarabine (DNM+Ara‐C)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 143
Study: 2845348

Group type: EXPERIMENTAL
Intervention: trimethoprim‐polymyxin B (TP)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: gentamicin sulfate (GS)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: sodium sulfacetamide (SS)
Number of subjects: 158
Study: 31808376

Group type: EXPERIMENTAL
Intervention: Type 1 Teamwork program
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 162
Study: 30541492

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE; maximum of 16 sessions in 16 weeks)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intensified Prolonged Exposure (iPE; maximum of 12 sessions in four weeks and two booster sessions)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Phase-based Treatment (PBT; maximum of eight sessions skills training followed by eight sessions PE in 16 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 150
Study: 27353492

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 26182736

Group type: EXPERIMENTAL
Intervention: Capsule Tamsulosin 0.4 mg, 1 daily up to 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo, 1 Capsule daily up to 4 weeks
Number of subjects: 100
Study: 23890458

Group type: EXPERIMENTAL
Intervention: Lullaby music played via headphones at a volume of 50‐60 dB
Number of subjects: 90

Group type: COMPARATOR
Intervention: Silence (headphones placed on infants' ears with no music played)
Number of subjects: 90
Study: 20451698

Group type: EXPERIMENTAL
Intervention: Intensive caffeine history screening
Number of subjects: 194

Group type: COMPARATOR
Intervention: Routine caffeine history screening
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Detectable serum caffeine
Number of subjects: 194
Study: 18187607

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17006068

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pressure-Support Ventilation (PSV)
Number of subjects: 12
Study: 12701015

Group type: EXPERIMENTAL
Intervention: Real-time magnetic endoscope imaging (MEI)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No MEI view (Control)
Number of subjects: 71
Study: 9701971

Group type: EXPERIMENTAL
Intervention: Writing (handwriting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tracing or writing without feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Writing in reverse or random orders
Number of subjects: 0
Study: 7718374

Group type: EXPERIMENTAL
Intervention: Post-tetanic burst (PTB) stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Post-tetanic twitch (PTT) stimulation
Number of subjects: 30
Study: 2509910

Group type: EXPERIMENTAL
Intervention: Deprenyl (10 mg per day)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 61122

Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31315279

Group type: EXPERIMENTAL
Intervention: High-CGA coffee (369 mg CGA/serving)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control coffee (35 mg CGA/serving)
Number of subjects: 150
Study: 28705592

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (bolus injection of 1.5 mg/kg at induction, continuous infusion of 2 mg/kg/h until end of surgery)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study: 24158328

Group type: EXPERIMENTAL
Intervention: Reduced-size microchip (10.9×1.6 mm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Microchip implantation and control treatments
Number of subjects: 40
Study: 21157389

Group type: EXPERIMENTAL
Intervention: Instantaneous performance feedback (peak velocity) during squat jump exercises
Number of subjects: 13

Group type: COMPARATOR
Intervention: No feedback during squat jump exercises
Number of subjects: 13
Study: 19476827

Group type: EXPERIMENTAL
Intervention: Duct to mucosa pancreaticojejunostomy
Number of subjects: 197

Group type: COMPARATOR
Intervention: Invagination pancreaticojejunostomy
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Pancreas texture
Number of subjects: 197
Study: 17189870

Group type: EXPERIMENTAL
Intervention: Premeal insulin lispro + bedtime NPH
Number of subjects: 30

Group type: COMPARATOR
Intervention: Twice-daily NPH
Number of subjects: 30
Study: 15138912

Group type: EXPERIMENTAL
Intervention: Intraoperative neuraxial anesthesia
Number of subjects: 196

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 196
Study: 11472282

Group type: EXPERIMENTAL
Intervention: Methohexitone 0.5 mg kg(‐1) combined with remifentanil 1.0 microg kg(‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methohexitone 0.75 mg kg(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 10
Study: 9677017

Group type: EXPERIMENTAL
Intervention: Elevated plasma total homocysteine concentration (over 11.5 micromol/L)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Plasma total homocysteine concentration below 11.5 micromol/L
Number of subjects: 513
Study: 8017450

Group type: EXPERIMENTAL
Intervention: Cyclic medroxyprogesterone plus calcium carbonate (n = 16)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclic medroxyprogesterone with calcium placebo (n = 16)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo medroxyprogesterone with active calcium (n = 15)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both medroxyprogesterone and calcium placebos (n = 14)
Number of subjects: 61
Study: 1851894

Group type: EXPERIMENTAL
Intervention: 6 mg of sumatriptan succinate subcutaneously
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Second injection of sumatriptan (n = 187)
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Placebo (n = 370)
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Placebo (n = 335)
Number of subjects: 1104
Study: 795496

Group type: EXPERIMENTAL
Intervention: Single dose of lincomycin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no lincomycin)
Number of subjects: 100
Study: 31399915

Group type: EXPERIMENTAL
Intervention: Early combination therapy with gentamicin (treatment started within 48 hours of culture results and continued for a minimum of 7 days)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Monotherapy with penicillin-based treatment
Number of subjects: 190

Group type: COMPARATOR
Intervention: Other treatments (not specified)
Number of subjects: 190
Study: 28686664

Group type: EXPERIMENTAL
Intervention: Lower dose of hydrocortisone (0.2-0.3 mg HC/kg body weight/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Higher dose of hydrocortisone (0.4-0.6 mg HC/kg body weight/day)
Number of subjects: 46
Study: 25085709

Group type: EXPERIMENTAL
Intervention: COMP (with opponent avatar)
Number of subjects: 15

Group type: COMPARATOR
Intervention: SELF (with self avatar)
Number of subjects: 15

Group type: COMPARATOR
Intervention: DO (no avatar)
Number of subjects: 15
Study: 23507972

Group type: EXPERIMENTAL
Intervention: Blink Intensive Tears (RE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optive Eye Drops (LE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both eyedrops after 21 days
Number of subjects: 20
Study: 21797835

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Light exposure
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combination treatment (walking, light, and sleep education)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Walking and light exposure adherence (4 d/wk)
Number of subjects: 132
Study: 19855319

Group type: EXPERIMENTAL
Intervention: Deadlift (5 repetitions at 5 repetitions maximum)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tuck jump (5 repetitions)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isometric MVC knee extensions (3 repetitions for 3 s)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control warm up
Number of subjects: 12
Study: 16892789

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16675760

Group type: EXPERIMENTAL
Intervention: Standard mood stabilizers (lithium, valproate, or carbamazepine)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Novel anticonvulsants
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Second-generation neuroleptics
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Standard mood stabilizer monotherapy
Number of subjects: 500
Study: 14570781

Group type: EXPERIMENTAL
Intervention: Dopexamine at the rate of 0.25 microg kg(‐1) min(‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline 0.9% (control)
Number of subjects: 100
Study: 10614791

Group type: EXPERIMENTAL
Intervention: Point-of-care qualitative troponin T test at enrollment
Number of subjects: 12666

Group type: COMPARATOR
Intervention: Alteplase or reteplase (thrombolysis treatment)
Number of subjects: 12666
Study: 7699662

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 3006

Group type: EXPERIMENTAL
Intervention: Tender point counts
Number of subjects: 3006

Group type: EXPERIMENTAL
Intervention: Decreased pain threshold
Number of subjects: 3006
Study: 2147930

Group type: EXPERIMENTAL
Intervention: sulbactam-ampicillin
Number of subjects: 40

Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 40
Study: 7204284

Group type: EXPERIMENTAL
Intervention: Behavioral parent training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Client-centered parent counseling
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait control group
Number of subjects: 36
Study: 30825082

Group type: EXPERIMENTAL
Intervention: Project SEARCH plus ASD Supports (PS + ASD)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 156
Study: 29921041

Group type: EXPERIMENTAL
Intervention: Carboxytherapy using carbon dioxide (CO2) injection
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intradermal injection of autologous platelet-rich plasma (PRP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tripolar radiofrequency (RF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 45
Study: 28905475

Group type: EXPERIMENTAL
Intervention: Bovine bone mineral (bbm) grafting
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naturally healing sockets (nat)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bovine bone mineral (bbm) in molars
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naturally healing sockets (nat) in molars
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bovine bone mineral (bbm) in premolars
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naturally healing sockets (nat) in premolars
Number of subjects: 24
Study: 25239018

Group type: EXPERIMENTAL
Intervention: Daily pain assessment using Pain Assessment in Advanced Dementia
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Higher levels of average daily pain
Number of subjects: 103
Study: 23620782

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Healthy Control (Replication Sample)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Healthy Control (Main Sample)
Number of subjects: 67
Study: 21949163

Group type: EXPERIMENTAL
Intervention: EMR reminder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMR reminder plus panel manager
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 19702706

Group type: EXPERIMENTAL
Intervention: Immediate cataract surgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Deferred cataract surgery
Number of subjects: 56
Study: 17481879

Group type: EXPERIMENTAL
Intervention: Montelukast 10mg for 12 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Budesonide 1600 mcg/day for 12 weeks
Number of subjects: 75
Study: 15018343

Group type: EXPERIMENTAL
Intervention: Interdisciplinary rounds (IRs)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 84
Study: 9257206

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Air
Number of subjects: 106
Study: 8302788

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: External beam radiotherapy (EBRT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Surgery alone (for stage I patients)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Local disease control
Number of subjects: 26
Study: 3771951

Group type: EXPERIMENTAL
Intervention: Standardized grass extract immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (no standardized grass extract)
Number of subjects: 0
Study: 28025967

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate tablet 50 mg (Jinge®, Test)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sildenafil citrate tablet 100 mg (Viagra®, Reference)
Number of subjects: 32
Study: 31026037

Group type: EXPERIMENTAL
Intervention: Enhancing Trauma Awareness course (6 sessions over 12 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No course (control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Enhancing Trauma Awareness course
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Focus group feedback from intervention teachers
Number of subjects: 96